Phase 1 Soon Recruiting: MK-2400 (Ifinatamab Deruxtecan) for Metastatic Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: The COSMYC Trial, ZEN-3694 Combination With BAT
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 2 Trial Enrolling: Combination Therapy for Metastatic Castration-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 1 Enrolling: Sylvester Cancer Center Launches Innovative Clinical Trial for High-Grade Neuroendocrine Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxUpdate: FC705 Signals a Leap Forward in Prostate Cancer Therapy, Outperforming Pluvicto
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 1 Results: Personalized Cancer Vaccine PGV001 Shows Promise Across Multiple Cancer Types
/in Clinical Trial, Not PCa related/by MaxIDOV-Immune A Viral Therapy Turning the Tide Against Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 for TTX-MC138: Breakthrough RNA Therapeutic Advances in Targeting Metastatic Cancers
/in Clinical Trial, Metastatic, Phase 1/by MaxUPDATE On ENV105: Safety Lead-In Completed for This Innovative Therapy
/in Clinical Trial, Metastatic, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- News pre|CISION Platform: Delivering Two Complementary Therapies from One Molecule October 27, 2025
- Helicon Degraders Show a New Path in Prostate Cancer Therapy October 27, 2025
- UPDATE 2: HLD-0915 Shows Promising Early Results in Drug-Resistant Prostate Cancer October 27, 2025
- Newsletter 43/2025 October 26, 2025